Nature of the Event
This is a regulatory filing submitted to BSE Limited, constituting a revised submission of the Audited Standalone and Consolidated Financial Results for the quarter and year ended March 31, 2026. The revision was necessitated to correct a typographical error in the original submission dated 30th May 2026. The results were approved by the Board of Directors at a meeting held on 30th May 2026, which commenced at 05:00 PM and concluded at 07:20 PM IST.
Standalone Financial Performance (Rs. in Lakhs)
Quarterly Performance (Q4 FY26)
- Total Revenue: ₹409.83 Lakhs
- Revenue from Operations: ₹409.17 Lakhs
- Other Income: ₹6.62 Lakhs
- Total Expenses: ₹395.11 Lakhs
- Cost of Materials Consumed: ₹362.29 Lakhs
- Change in Inventories: ₹(-73.66) Lakhs (Credit)
- Employee Benefits Expense: ₹8.07 Lakhs
- Finance Cost: ₹4.67 Lakhs
- Depreciation & Amortization: ₹3.21 Lakhs
- Other Expenses: ₹4.60 Lakhs
- Profit Before Tax: ₹147.18 Lakhs
- Tax Expense: ₹38.59 Lakhs
- Current Tax: ₹41.73 Lakhs
- Deferred Tax: ₹(-3.14) Lakhs (Credit)
- Profit After Tax (Net Profit): ₹108.59 Lakhs
- Paid-up Equity Share Capital: ₹4,223.12 Lakhs (Face Value ₹10/- each)
- Earnings Per Share (EPS):
- Basic EPS: ₹0.288
- Diluted EPS: ₹0.275
Full Year Performance (FY26)
- Total Revenue: ₹1,561.87 Lakhs
- Revenue from Operations: ₹1,559.95 Lakhs
- Other Income: ₹19.15 Lakhs
- Total Expenses: ₹1,453.21 Lakhs
- Profit Before Tax: ₹1,086.56 Lakhs
- Tax Expense: ₹275.01 Lakhs
- Current Tax: ₹258.84 Lakhs
- Deferred Tax: ₹16.17 Lakhs
- Profit After Tax (Net Profit): ₹811.55 Lakhs
- Earnings Per Share (EPS):
- Basic EPS: ₹4.757
- Diluted EPS: ₹4.310
Consolidated Financial Performance (Rs. in Lakhs)
Includes subsidiary Sriven Pharmachem India Private Limited.
Quarterly Performance (Q4 FY26)
- Total Revenue: ₹1,341.45 Lakhs
- Revenue from Operations: ₹1,340.49 Lakhs
- Other Income: ₹9.62 Lakhs
- Profit After Tax (Net Profit): ₹767.99 Lakhs
- Earnings Per Share (EPS):
- Basic EPS: ₹2.039
- Diluted EPS: ₹1.947
Full Year Performance (FY26)
- Total Revenue: ₹2,493.49 Lakhs
- Revenue from Operations: ₹2,491.27 Lakhs
- Other Income: ₹22.15 Lakhs
- Profit After Tax (Net Profit): ₹1,470.94 Lakhs
- Earnings Per Share (EPS):
- Basic EPS: ₹8.622
- Diluted EPS: ₹7.811
Subsidiary Information
- Name: Sriven Pharmachem India Private Limited (Wholly-owned subsidiary)
- Country of Incorporation: India
- Financials (Period from 14-01-2026 to 31-03-2026):
- Total Assets: ₹19,313.92 Lakhs
- Total Revenue: ₹9,418.27 Lakhs
- Net Profit After Tax: ₹659.40 Lakhs
- Total Comprehensive Income: ₹659.40 Lakhs
- Net Cash Outflows: ₹488.06 Lakhs
Key Balance Sheet Highlights (Standalone as of 31-03-2026)
- Total Assets: ₹39,957.20 Lakhs
- Non-Current Assets: ₹29,631.17 Lakhs
- Property, Plant and Equipment: ₹1,135.84 Lakhs
- Right-of-use-asset: ₹74.85 Lakhs
- Investment in Sriven Pharmachem: ₹27,716.95 Lakhs
- Current Assets: ₹10,326.03 Lakhs
- Inventories: ₹2,817.54 Lakhs
- Trade Receivables: ₹7,230.17 Lakhs
- Total Equity: ₹32,716.32 Lakhs
- Share Capital: ₹4,223.12 Lakhs
- Other Equity: ₹28,493.20 Lakhs
- Total Liabilities: ₹7,240.88 Lakhs
Cash Flow Statement Highlights (Standalone FY26)
- Net Cash from Operating Activities: ₹(-307.57) Lakhs (Used in)
- Net Cash from Investing Activities: ₹(-128.47) Lakhs (Used in)
- Investment in Sriven Pharma (Cash): ₹(-29.53) Lakhs
- Net Cash from Financing Activities: ₹454.67 Lakhs
- Share Warrants Amount Received: ₹617.98 Lakhs
Additional Notes from Management
- The company operates in a single business segment: 'Manufacturing and Trading of all kind of active Pharmaceutical Ingredients (Bulk Drugs)'.
- The company changed its name from Macro International Limited due to a change in business activity.
- The financial results are prepared in accordance with Indian Accounting Standards (Ind AS).
- The results are available on the company's website: https://astallabs.com/.